Target therapies in systemic lupus erythematosus: current state of the art.
Wiesik-Szewczyk
E
E
Institute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, Poland. ewa.w.szewczyk@gmail.com
Lacki
J K
JK
Feleszko
W
W
Olesinska
M
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D023201:CD40 Ligand / Q000276:immunology; D060908:CTLA-4 Antigen; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000209:etiology / Q000628:therapy*; D009930:Organic Chemicals / Q000276:immunology; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018951:Antigens, CD20; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D015850:Interleukin-6; D009930:Organic Chemicals; D051918:Sialic Acid Binding Ig-like Lectin 2; C029248:Tolerogen; D014409:Tumor Necrosis Factor-alpha; D023201:CD40 Ligand